Pharmacokinetic and Pharmacodynamic Characteristics of Tegoprazan According to Helicobacter pylori Infection Status
Abstract
Objective: Tegoprazan is a novel potassium-competitive acid blocker (P-CAB) used to treat acid-related diseases. This study aimed to evaluate the effect of the H. pylori infection status on the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics and safety of tegoprazan.
Methods: This study involved two cohorts. In Cohort 1, 12 H. pylori-negative subjects were administered tegoprazan at 50 or 100 mg for 7 days. In Cohort 2, four subjects positive for H. pylori received 50 and 100 mg of tegoprazan in a single dose crossover study. We estimated the PK parameters using non-compartment analysis and measured PD parameters using an intragastric pH monitor.
Results: The PK and PD of tegoprazan in both groups were dose-dependent. The Cmax of each dose of tegoprazan in subjects with H. pylori decreased more than in the H. pylori negative group, but the AUClast and AUCinf of the two groups were similar. All PD parameters in H. pylori-positive subjects increased more than in the negative group, which suggests that tegoprazan's intragastric acid suppression is enhanced in cases of H. pylori.
Conclusion: The presence of H. pylori did not have a clinically significant effect on tegoprazan's PK and tolerability, but significantly enhanced its intragastric acid suppression efficacy.
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2018
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study
- Occupation and risk of severe COVID-19: prospective cohort study of 120,075 UK Biobank participants
- Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study
- Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.